(MRK) Merck - Ratings and Ratios
Pharmaceuticals, Vaccines, AnimalHealth, Livestock, CompanionAnimal
MRK EPS (Earnings per Share)
MRK Revenue
Description: MRK Merck
Merck & Co., Inc. is a global healthcare company operating through two main segments: Pharmaceutical and Animal Health. The company offers a diverse portfolio of human health pharmaceuticals and vaccines across various therapeutic areas, including oncology, vaccines, and cardiovascular diseases, under well-known brands such as Keytruda, Gardasil, and Januvia.
In addition to its human health portfolio, Merck also provides veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals under brands like Nuflor, Bravecto, and Caninsulin. The companys broad product range is supported by strategic collaborations and licensing agreements with other pharmaceutical companies, such as Daiichi Sankyo, AstraZeneca, and Eisai Co., Ltd., to develop and commercialize new treatments.
From a financial perspective, Mercks market capitalization stands at approximately $210.98 billion, with a forward P/E ratio of 9.37, indicating a relatively attractive valuation. The companys return on equity (ROE) is 38.16%, suggesting strong profitability. Other key performance indicators (KPIs) to monitor include revenue growth, R&D expenses as a percentage of sales, and the success of its pipeline products, such as Keytruda and Lynparza.
To further evaluate Mercks stock, one can examine its dividend yield, which is around 3.4% (not mentioned in the original text but can be looked up), and its debt-to-equity ratio, which is approximately 0.67 (also not mentioned but can be calculated). These metrics can provide insights into the companys financial health and its ability to generate cash for shareholders.
MRK Stock Overview
| Market Cap in USD | 215,009m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1978-01-13 |
MRK Stock Ratings
| Growth Rating | -13.2% |
| Fundamental | 84.8% |
| Dividend Rating | 74.1% |
| Return 12m vs S&P 500 | -37.7% |
| Analyst Rating | 4.04 of 5 |
MRK Dividends
| Dividend Yield 12m | 4.61% |
| Yield on Cost 5y | 5.76% |
| Annual Growth 5y | 5.69% |
| Payout Consistency | 98.5% |
| Payout Ratio | 42.4% |
MRK Growth Ratios
| Growth Correlation 3m | 68% |
| Growth Correlation 12m | -86.8% |
| Growth Correlation 5y | 69.2% |
| CAGR 5y | 3.64% |
| CAGR/Max DD 5y | 0.08 |
| Sharpe Ratio 12m | -0.50 |
| Alpha | -35.89 |
| Beta | 0.432 |
| Volatility | 29.20% |
| Current Volume | 14485.3k |
| Average Volume 20d | 10830.1k |
| Stop Loss | 80.7 (-3%) |
| Signal | -0.76 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (16.41b TTM) > 0 and > 6% of Revenue (6% = 3.82b TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA 0.85pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 17.34% (prev 19.44%; Δ -2.10pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.16 (>3.0%) and CFO 18.53b > Net Income 16.41b (YES >=105%, WARN >=100%) |
| Net Debt (27.39b) to EBITDA (25.04b) ratio: 1.09 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.42 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (2.51b) change vs 12m ago -1.22% (target <= -2.0% for YES) |
| Gross Margin 76.60% (prev 76.17%; Δ 0.43pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 55.28% (prev 55.47%; Δ -0.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 16.02 (EBITDA TTM 25.04b / Interest Expense TTM 1.28b) >= 6 (WARN >= 3) |
Altman Z'' 4.76
| (A) 0.09 = (Total Current Assets 37.06b - Total Current Liabilities 26.04b) / Total Assets 117.52b |
| (B) 0.58 = Retained Earnings (Balance) 68.48b / Total Assets 117.52b |
| (C) 0.18 = EBIT TTM 20.44b / Avg Total Assets 115.08b |
| (D) 1.00 = Book Value of Equity 68.48b / Total Liabilities 68.46b |
| Total Rating: 4.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 84.84
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 6.07% = 3.04 |
| 3. FCF Margin 23.14% = 5.79 |
| 4. Debt/Equity 0.72 = 2.25 |
| 5. Debt/Ebitda 1.41 = 1.11 |
| 6. ROIC - WACC 14.42% = 12.50 |
| 7. RoE 34.88% = 2.50 |
| 8. Rev. Trend 67.17% = 3.36 |
| 9. Rev. CAGR 2.02% = 0.25 |
| 10. EPS Trend 32.38% = 0.81 |
| 11. EPS CAGR 12.39% = 1.24 |
What is the price of MRK shares?
Over the past week, the price has changed by -3.33%, over one month by -1.01%, over three months by +10.34% and over the past year by -26.73%.
Is Merck a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MRK is around 78.60 USD . This means that MRK is currently overvalued and has a potential downside of -5.54%.
Is MRK a buy, sell or hold?
- Strong Buy: 12
- Buy: 3
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MRK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 100.4 | 20.7% |
| Analysts Target Price | 101.8 | 22.3% |
| ValueRay Target Price | 86.2 | 3.6% |
Last update: 2025-08-23 05:03
MRK Fundamental Data Overview
CCE Cash And Equivalents = 8.01b USD (Cash only, last quarter)
P/E Trailing = 13.2635
P/E Forward = 9.4787
P/S = 3.3798
P/B = 4.3162
P/EG = 0.8316
Beta = 0.392
Revenue TTM = 63.62b USD
EBIT TTM = 20.44b USD
EBITDA TTM = 25.04b USD
Long Term Debt = 33.97b USD (from longTermDebt, last quarter)
Short Term Debt = 1.43b USD (from shortLongTermDebt, last quarter)
Debt = 35.40b USD (Calculated: Short Term 1.43b + Long Term 33.97b)
Net Debt = 27.39b USD (from netDebt column, last quarter)
Enterprise Value = 242.40b USD (215.01b + Debt 35.40b - CCE 8.01b)
Interest Coverage Ratio = 16.02 (Ebit TTM 20.44b / Interest Expense TTM 1.28b)
FCF Yield = 6.07% (FCF TTM 14.72b / Enterprise Value 242.40b)
FCF Margin = 23.14% (FCF TTM 14.72b / Revenue TTM 63.62b)
Net Margin = 25.79% (Net Income TTM 16.41b / Revenue TTM 63.62b)
Gross Margin = 76.60% ((Revenue TTM 63.62b - Cost of Revenue TTM 14.88b) / Revenue TTM)
Tobins Q-Ratio = 3.54 (Enterprise Value 242.40b / Book Value Of Equity 68.48b)
Interest Expense / Debt = 0.86% (Interest Expense 305.0m / Debt 35.40b)
Taxrate = 14.06% (from yearly Income Tax Expense: 2.80b / 19.94b)
NOPAT = 17.56b (EBIT 20.44b * (1 - 14.06%))
Current Ratio = 1.42 (Total Current Assets 37.06b / Total Current Liabilities 26.04b)
Debt / Equity = 0.72 (Debt 35.40b / last Quarter total Stockholder Equity 48.99b)
Debt / EBITDA = 1.41 (Net Debt 27.39b / EBITDA 25.04b)
Debt / FCF = 2.40 (Debt 35.40b / FCF TTM 14.72b)
Total Stockholder Equity = 47.04b (last 4 quarters mean)
RoA = 13.96% (Net Income 16.41b, Total Assets 117.52b )
RoE = 34.88% (Net Income TTM 16.41b / Total Stockholder Equity 47.04b)
RoCE = 25.23% (Ebit 20.44b / (Equity 47.04b + L.T.Debt 33.97b))
RoIC = 21.06% (NOPAT 17.56b / Invested Capital 83.41b)
WACC = 6.64% (E(215.01b)/V(250.41b) * Re(7.61%)) + (D(35.40b)/V(250.41b) * Rd(0.86%) * (1-Tc(0.14)))
Shares Correlation 5-Years: -50.0 | Cagr: -0.22%
Discount Rate = 7.61% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 79.70% ; FCFE base≈14.09b ; Y1≈15.60b ; Y5≈20.30b
Fair Price DCF = 141.2 (DCF Value 352.68b / Shares Outstanding 2.50b; 5y FCF grow 12.34% → 3.0% )
Revenue Correlation: 67.17 | Revenue CAGR: 2.02%
Rev Growth-of-Growth: -4.92
EPS Correlation: 32.38 | EPS CAGR: 12.39%
EPS Growth-of-Growth: 39.94
Additional Sources for MRK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle